Introduction
============

Nasopharyngeal carcinoma (NPC) primarily occurs in the epithelial lining of the nasopharynx and is one of the primary head and neck tumor types ([@b1-mmr-17-06-7513]). It is prevalent in Southern China and East Asia, Greenland (native), Canada (Northwest Territories), and Alaska ([@b2-mmr-17-06-7513],[@b3-mmr-17-06-7513]). The health status of patients under intensity-modulated radiation therapy and concurrent chemoradiotherapy were improved, however, the prognosis of patients with NPC with distant metastasis remains poor ([@b4-mmr-17-06-7513]). Therefore, further investigation of the molecular mechanisms of NPC metastasis and development of effective treatment strategies is required in order to develop individualized treatment for patients with the disease.

A previous study demonstrated that cancer-associated mortalities caused by malignant tumors are associated with metastasis ([@b5-mmr-17-06-7513]). The tumor cell microenvironment serves a role during tumor progression, including metastasis ([@b6-mmr-17-06-7513]). Transforming growth factor-β (TGF-β) is a key cytokine in the tumor microenvironment, which serves an important regulatory role in tumorigenesis and development ([@b7-mmr-17-06-7513]). The best-known epithelial-mesenchymal transition (EMT) pathway is induced by TGF-β and causes epithelial cells to generate mesenchymal phenotypes and subsequently enables them to promotes their development ([@b8-mmr-17-06-7513],[@b9-mmr-17-06-7513]). It has been demonstrated that an increase in the expression of miR-9-3p suppresses the metastasis of NPC via inhibition of the EMT process, thereby providing a series of therapeutic targets for the treatment of NPC ([@b10-mmr-17-06-7513]). Pigment epithelium-derived factor functions as a tumor-suppressor gene in the occurrence of EMT and metastasis in NPC ([@b11-mmr-17-06-7513]). Thus, investigation of therapeutic approaches targeting EMT pathways may be promising for patients with NPC.

Traditional Chinese medicine (TCM) has been used for the treatment of cancer for more than 2,000 years ([@b12-mmr-17-06-7513]). Curcumol is extracted from the roots of the medicinal plant *Rhizoma curcumae* as a guaiane-type sesquiterpenoid hemiketal ([@b13-mmr-17-06-7513]). There is a previous study on tumor treatment in clinical or scientific research focusing on TCM treatment with low toxicity and drug resistance ([@b14-mmr-17-06-7513]). Previous studies have also demonstrated that Curcumol possesses antitumor, anti-hepatic fibrosis, antiproliferation, anti-inflammatory, antioxidant and antimicrobial activities ([@b15-mmr-17-06-7513],[@b16-mmr-17-06-7513]). In addition, Curcumol suppresses human cancer cell growth and promotes apoptosis activity in several types of cancer, including cervical cancer, breast cancer, lung cancer, gastric cancer and hepatocarcinoma ([@b17-mmr-17-06-7513],[@b18-mmr-17-06-7513]). Chen *et al* ([@b19-mmr-17-06-7513]) demonstrated that Curcumol induces HSC-T6 apoptosis at a concentration of 300 µM and has few side effects on normal liver cell line BRL-3A. Although Curcumol exhibits antitumor activity, the mechanism of action remains unknown. Furthermore, the effect of Curcumol on the occurrence and development of NPC remains unclear. Therefore, the current study investigated the effect of Curcumol on NPC with regards to metastasis.

Materials and methods
=====================

### Cell culture and animals

All experiments were performed in the Central Laboratory of the North Sichuan Medical College (Sichuan, China). Human NPC 5--8F cells were provided by the Shanghai Institute for Biological Sciences (Shanghai, China). Cells were cultured in RPMI 1640 medium (Hyclone; GE Healthcare Life Sciences, Logan, UT, USA) with 10% fetal bovine serum (FBS; Hyclone; GE Healthcare Life Sciences) and maintained with 5% CO~2~ at 37°C. A total of 20 female BALB/C athymic nude mice, aged 4--6 weeks and weighing 18--20 g, were purchased from the Institute of Zoology, Chinese Academy of Sciences (Beijing, China) and housed in a sterile environment at 25°C with a 12-h light/dark cycle and 40% humidity, and food and water sterilized by high pressure used to feed the mice *ad libitum*. Curcumol was dissolved to a concentration of 10 mg/ml in absolute ethyl alcohol and then diluted with the 10% FBS RPMI-1640 medium (adjustment based on the required concentration of the drug). Cells without Curcumol treatment (0 µΜ/ml) served as a control group. Animal experiments were approved by the Affiliated Hospital of North Sichuan Medical College ethics committee (CBYXY0022).

### Drugs and reagents

Curcumol (cat. no. 100185-200506) was purchased from MedChemExpress (Monmouth Junction, NJ, USA). A cell counting kit-8 (CCK-8) assay kit was obtained from Dojindo Molecular Technologies, Inc. (Kumamoto, Japan). Dimethyl sulfoxide (DMSO) was purchased from Beyotime Institute of Biotechnology (Haimen, China) and used for the storage of cells. The purified recombinant human TGF-β1 powder (R&D Systems, Inc., Minneapolis, MN USA) was dissolved in 4 mM HCl containing 1 mg/ml bovine serum albumin (Shanghai Yi Sheng Biotechnology Co., Ltd., Shanghai, China; storage concentration: 50 ng/ml). Curcumol was diluted with media to different concentrations prior to use. Matrigel was purchased from BD Biosciences (Franklin Lakes, NJ, USA). Transwell inserts were provided by Corning Costar Co., Ltd. (Corning, NY, USA). Rabbit polyclonal antibodies against E-cadherin (cat. no. 3195), N-cadherin (cat. no. 13116) and β-actin (cat. no. 3700) were purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA). Goat anti-TGF-β1 (cat. no. TA130016), rabbit monoclonal antibody for β-actin (cat. no. TA130008), horseradish peroxidase (HRP)-conjugated goat anti-mouse (cat. no. TA130010) and goat anti-rabbit (cat. no. TA130020) immunoglobulin G were purchased from OriGene Technologies, Inc. (Rockville, MD, USA). The enhanced chemiluminescence (ECL) reagent was purchased from EMD Millipore (Billerica, MA, USA). The reagents for quantitative polymerase chain reaction (qPCR) were obtained from Takara Biotechnology Co., Ltd. (Dalian, China). Other chemicals were of standard analytical grade.

### Curcumol treatment in vitro

RPMI-1640 culture medium without FBS was used as the primary solvent with the following treatments: i) Control group, cells without Curcumol (0 µM/ml) treatment; ii) 0.1 µM/ml Curcumol group; iii) 0.2 µM/ml Curcumol group; iv) 0.4 µM/ml Curcumol group. Following mixing of the medium, serum and Curcumol according to the concentration requirement, cells were cultured in 37°C with 5% CO~2~.

### Cell viability assay

Cell viability was detected using a CCK-8 assay. Cells were seeded in 100 µl complete medium in 96-well plates at a density of 5×10^5^/ml and triplicate wells were used for each group. Following 8 h incubation at 37°C, cells were exposed to different doses of Curcumol for 48 h in 96-well plates. A solution of 10 µl CCK-8 and 90 µl FBS-free medium was added to each well and incubated for a further 10 min at 37°C. A wavelength of 450 nm was then used to measure cell viability.

### Apoptosis detected by flow cytometry (FCM)

Curcumol-induced cell apoptosis was detected by FCM using an Annexin V-fluorescein isothiocyanate (FITC) apoptosis detection kit (Beyotime Institute of Biotechnology). Briefly, following conditions of cell culture described above, all cells were harvested and washed with cold PBS twice and then treated with different concentrations of Curcumol for 48 h at 37°C. Cells were stained with Annexin propidium iodide and V-FITC following centrifugation (100 × g for 5 min at 25°C) and using a flow cytometer and BD CellQuest Pro software version 5.1 (BD Biosciences, Franklin Lakes, NJ, USA).

### Cell invasion and migration assay

A wound-healing assay was performed using 5--8F treated cells. A total of 8×10^5^ cells were incubated in 6-well plates and grown to confluence. An artificial homogenous wound was created in the cell monolayer with a sterile 100 µl tip and was then washed with PBS to remove cell debris. Cells were then treated with different concentrations of Curcumol for 24 and 48 h. The wound healing rate following treatment was evaluated using ImageJ software version k1.45 (National Institutes of Health, Bethesda, MD, USA). Transwell chambers (8 µm pore size; EMD Millipore) with Matrigel were used to detected cell invasion. Cells (1×10^4^) were treated with Curcumol for 48 h and were then plated in the top chambers with an 8 µm membrane pore in FBS-free medium. The medium in the bottom chamber was supplemented with 10% FBS to allow for invasion for 24 h at 37°C. At the end of the experiment, cells at the bottom of the membrane were fixed in 4% paraformaldehyde for 10 min at 37°C and stained with 1% crystal violet at 25°C (Sigma-Aldrich; Merck KGaA, Darmstadt Germany) for 10 min. Images were captured using a light microscope at a magnification of ×100. The specific number of cells per filter in five predetermined fields was then counted and analyzed.

### Reverse transcription-qPCR (RT-qPCR)

Total RNA was extracted from 5--8F cells using TRIzol (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA), according to the manufacturer\'s protocol. RNA was then reverse transcribed into cDNA using an M-MLV kit (Takara Biotechnology Co., Ltd.). All PCR primers were as follows: E-cadherin, forward, 5′-GGTTATTCCTCCCATCAGCT-3′ and reverse, 5′-CTTGGCTGAGGAGGGTGTA-3′; N-cadherin, forward, 5′-GGTGGAGGAGAAGAAGACCAG-3′ and reverse, 5′-GGCATCAGGCTCCACAGT-3′; GAPDH, forward, 5′-TTCGTCATGGGTGTGAAC-3′ and reverse, 5′-AGTGAGCTTCCCGTTCAGC-3′. The qPCR assay (95°C for 30 sec, then 40 cycles of 95°C for 5 sec and 60°C for 30 sec) was performed as the instruction in triplicate using SYBR Green PCR Master mix and Applied Biosystems Prism 7500 (Applied Biosystems; Thermo Fisher Scientific, Inc.). The relative fold change among groups was analyzed using 2^−ΔΔCq^ quantitative analysis ([@b20-mmr-17-06-7513]).

### Western blot analysis

Cells treated with Curcumol were lysed in radioimmunoprecipitation lysis buffer (Beyotime Institute of Biotechnology) on ice for 30 min. Cells were then centrifuged at 100 × g for 15 min at 4°C and the protein concentration was determined using a BCA protein assay kit (Beyotime Institute of Biotechnology). Equal amounts (25 µg) of total protein samples were separated using 10% SDS-PAGE and different protein bands were transferred to polyvinylidene fluoride membranes (EMD Millipore). Membranes were blocked using 0.1% TBST with 5% non-fat dry milk at room temperature for 1 h and incubated with E-cadherin (dilution: 1:1,000), N-cadherin (dilution: 1:1,000) and anti-β-actin (dilution: 1:4,000) at 4°C overnight. Membranes were then washed using 0.1% TBST four times and incubated with HRP-conjugated secondary antibodies for 1.5 h at room temperature. The target protein was detected by ECL and the bands were quantified using ImageJ software version k1.45.

### ELISA

Pretreated serum samples and cell supernatants were dissolved on ice and a TGF-β1 ELISA kit (cat. no. ab100647; Abcam, Cambridge, UK) was used to measure the TGF-β1 concentrations in accordance with the manufacturer\'s protocols. Each sample was run in triplicate. Standards, serum samples or cell supernatants were added to 96-well plates, respectively. Subsequently, the enzyme conjugation solutions were added and the mixtures were co-incubated for 60 min at 37°C. Every well was washed 5 times with wash buffer. Substrate I and II were then added to each well respectively and the plate was kept away from light at room temperature for 15 min. The plate was then read at a wavelength of 450 nm using an ELISA reader.

### Xenograft tumor models

NPC 5--8F cells (1×10^7^) were resuspended with 200 µl PBS and Matrigel and subcutaneous injections were performed on both sides of the nude mice following anesthesia with ether. Mice were randomly assigned to a control group and a treated group when the tumors reached an average volume of 50 mm^3^ (volume=length × width 2/2). The treated group were administered with Curcumol at 15 µg/kg crude drug (sterile water solution, equivalent to the human dosage) by gavage twice a day for 35 days and the control group mice were given an equal volume of sterile water. The tumor volume was measured every 7 days. Mice were sacrificed by cervical dislocation and tumors and peripheral blood were collected. Following weighing of the tumor, the tumors were stored at −8°C. In addition, blood samples were centrifuged at 100 × g for 15 min at 25°C in order to obtain the serum and were then stored at −80°C.

### Statistical analysis

Data are presented as the mean ± standard error of the mean. Each experiment was repeated at least three times. Data were analyzed using SPSS 13.0 (SPSS Inc., Chicago, IL, USA). A Student\'s t-test was used to analyze differences between two groups, while the differences between \>2 groups were detected using one-way analysis of variance followed by Student-Newman-Keuls test. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Curcumol suppresses NPC cell proliferation and promotes NPC cell apoptosis

The effect of Curcumol on NPC 5--8F cell viability was investigated by determining the growth of 5--8F cells using a CCK-8 assay. The results demonstrated that Curcumol significantly inhibited cell growth at doses of 0.1, 0.2 and 0.4 µM/ml ([Fig. 1A](#f1-mmr-17-06-7513){ref-type="fig"}). 5--8F cell apoptosis was quantified using FCM. The results indicated that the rate of apoptosis was significantly increased following Curcumol treatment in a dose-dependent manner ([Fig. 1B and C](#f1-mmr-17-06-7513){ref-type="fig"}).

### Curcumol inhibits 5--8F cell invasion and migration

A wound-healing assay and Transwell assays were performed to investigate whether Curcumol treatment affected the migration and invasion ability of NPC cells ([Fig. 2](#f2-mmr-17-06-7513){ref-type="fig"}). The migration ability of cells was significantly decreased with an increase of the concentration of Curcumol compared with that in the control group ([Fig. 2A and C](#f2-mmr-17-06-7513){ref-type="fig"}). Cell invasion was significantly decreased in a dose-dependent manner at different concentrations of Curcumol treatment ([Fig. 2B and D](#f2-mmr-17-06-7513){ref-type="fig"}).

### Effect of Curcumol on expression of EMT-associated genes

The mechanism of action of Curcumol on inhibition of 5--8F cell development was investigated by performing RT-qPCR and western blotting ([Fig. 3](#f3-mmr-17-06-7513){ref-type="fig"}). The results of RT-qPCR suggested that the expression of E-cadherin mRNA was significantly increased in 5--8F cells treated with Curcumol at doses of 0.1, 0.2 and 0.4 µM/ml ([Fig. 3A](#f3-mmr-17-06-7513){ref-type="fig"}). By contrast, the expression of N-cadherin was significantly inhibited in 5--8F cells treated with Curcumol in a dose-dependent manner ([Fig. 3B](#f3-mmr-17-06-7513){ref-type="fig"}). The results of western blotting were consistent with this ([Fig. 3C-F](#f3-mmr-17-06-7513){ref-type="fig"}). Thus, this suggests that Curcumol may regulate EMT-associated proteins in a dose-dependent manner.

### Curcumol inhibits the growth of transplanted tumors with 5--8F cells in vivo

Based on the results of experiments on 5--8F cells, further investigation was performed into the effect of Curcumol on NPC *in vivo*. The results indicated that the tumor volume of the Curcumol group on day 35 was significantly decreased compared with that in the control group ([Fig. 4A and B](#f4-mmr-17-06-7513){ref-type="fig"}). The tumor weight of the control group was also significantly increased compared with that in the Curcumol group ([Fig. 4C](#f4-mmr-17-06-7513){ref-type="fig"}), suggesting that Curcumol significantly inhibited the growth of tumors *in vivo*.

### Curcumol effected the expression of EMT-associated genes and the secretion of TGF-β1 in vivo

Tumors and serum were extracted from nude mice and western blotting and ELISA assays were performed to detect the expression of EMT-associated proteins and the secretion of TGF-β1. The expression of E-cadherin was significantly increased in the Curcumol group compared with the control group ([Fig. 5A](#f5-mmr-17-06-7513){ref-type="fig"}), while the expression of N-cadherin was significantly decreased in the Curcumol group ([Fig. 5B](#f5-mmr-17-06-7513){ref-type="fig"}). The expression of TGF-β1 in tumors and serum was measured by western blotting and ELISA. The concentration of TGF-β1 was significantly decreased in the Curcumol group compared with the control group ([Fig. 5C](#f5-mmr-17-06-7513){ref-type="fig"}) and the results of tumor analysis were consistent with this ([Fig. 5D](#f5-mmr-17-06-7513){ref-type="fig"}).

Discussion
==========

NPC is the most common malignant tumor of the nasopharynx mucosa and has regional distribution characteristics; the incidence in developing countries is higher compared with developed countries ([@b21-mmr-17-06-7513]). The application of intensity-modulated radiotherapy and platinum-based chemotherapy, which are used alone or in combination, has led to significant improvements in tumor control and long-term survival of patients with NPC ([@b22-mmr-17-06-7513]). However, metastasis remains an important factor in the treatment and prognosis of patients with NPC ([@b23-mmr-17-06-7513]). TCM has been developed for cancer research and many Chinese herbal medicines have been demonstrated to inhibit cancer. Celastrol is a triterpene from TCM, which demonstrates anti-proliferative activity in HONE-1 and NPC-039 cell lines and induces apoptosis through the death receptor and mitochondrial pathway in human NPC cells, which makes it a promising candidate in the development of drugs for treating NPC ([@b24-mmr-17-06-7513]). Evodiamine inhibits the migration and invasive ability of NPC cells and metastasis targeting matrix metalloproteinase-2 ([@b25-mmr-17-06-7513]). The aim of the current study was to identify a Chinese herbal medicine that targets the EMT pathway in order to inhibit metastasis of NPC.

EMT is one of the key factors serving a role in tumor progression ([@b26-mmr-17-06-7513]). It is a biological process in which epithelial cells lose their epithelial morphology, thereby improving their migration and invasive ability and giving them status as mesenchymal cells ([@b27-mmr-17-06-7513]). Thus, this suggests that the EMT pathway is vital in the invasion and metastasis ability of malignant tumors ([@b28-mmr-17-06-7513]). It has been suggested that TGF-β1 is the most important factor in the induction of EMT during development, cancer and other pathological conditions ([@b26-mmr-17-06-7513]). It has also been previously demonstrated that in HepG2 cell lines, simple TGF-β1 stimulation induces EMT ([@b29-mmr-17-06-7513]). In addition, the molecular hallmarks of EMT are mesenchymal and epithelial phenotypes, including the expression of E-cadherin and N-cadherin ([@b30-mmr-17-06-7513]). The metastasis of NPC is closely associated with the occurrence of EMT and previous study has indicated that inhibition of EMT may significantly suppress metastasis of NPC ([@b25-mmr-17-06-7513]). Therefore, investigation of EMT-associated medicine is required to improve the prognosis of patients with NPC.

Due to the lack of side effects, an increasing number of studies have focused on the biological activities of Curcumol. Curcumol exhibits multiple biological activities, including antitumor activity ([@b31-mmr-17-06-7513]). In addition, the mechanism of the anticancer activity of Curcumol was by inducing the expression of anti-oncogenes or inhibiting the expression of oncogenes. The results of the current study indicated that the viability of NPC 5--8F cells was significantly decreased following treatment with Curcumol and the rate of apoptosis was significantly increased in a dose-dependent manner, which provides basis for further study of the effect of Curcumol on NPC. The results of the wound-healing and Transwell assays confirmed that Curcumol reduced the migration and invasion ability of 5--8F cells. Furthermore, the expression of the primary regulatory proteins serving a role in the EMT pathway are also regulated by Curcumol. The results of the *in vivo* experiments also indicated that Curcumol significantly inhibited tumor growth and the inhibitory effect of the 0.4 µM/ml group was significantly higher compared with that of the control group. Furthermore, the results of *in vivo* experiments investigating the expression of EMT associated proteins were consistent with those on 5--8F cells. In addition, Curcumol inhibited the expression of TGF-β1 in tumors in nude mice and also inhibits the secretion of TGF-β1 in the serum of nude mice.

In conclusion, the current study investigated the effect of Curcumol in arresting cell migration against the human NPC5-8F cell line and also showed that the inhibition of TGF-β1 led to the decrease of EMT occurrence, which was considered a result of the anticancer activity of Curcumol. These results were also confirmed *in vivo* using a xenograft mouse model.

However, there are some limitations to the current study. Due to the funding of the project and the time schedule of the authors, only one cell line was selected for the experiment. Therefore, further studies using a greater number of cell lines are required to supplement the experimental results. However, the results of the current study did indicate the molecular mechanism of Curcumol, which may potentially improve the quality of life of patients with NPC in the future.

Not applicable.

Funding
=======

This study was funded by Sichuan Provincial Science and Technology Department of key projects (14ZA0198).

Availability of data and materials
==================================

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors\' contributions
=======================

DY did the majority of the experiments and wrote the paper. SD, WG, SL and YL helped perform the cell experiments. DY performed the statistical analysis.

Ethics approval and consent to participate
==========================================

Animal experiments were approved by Affiliated Hospital of North Sichuan Medical College hospital ethics committee (CBYXY0022). All procedures performed in studies were in accordance with the ethical standards.

Consent for publication
=======================

Not applicable.

Competing interests
===================

The authors declare that they have no competing interests.

![Curcumol inhibited the viability of NPC cells. (A) NPC cell viability. (B) Apoptosis rate of NPC cells. (C) Flow cytometry analysis of NPC cell apoptosis. Values are presented as mean ± standard error of the mean. \*P\<0.05, \*\*P\<0.01, vs. 0 µM/ml. NPC, nasopharyngeal carcinoma; OD, optical density; PI, propidium iodide; FITC, fluorescein isothiocyanate.](MMR-17-06-7513-g00){#f1-mmr-17-06-7513}

![Curcumol inhibited the invasion and migration ability of NPC cells. (A) Migration ability of NPC cells. (B) Invasion ability of NPC cells. (C) Quantification of migration ability of NPC cells. (D) Quantification of invasion ability of NPC cells. Values are presented as the mean ± standard error of the mean. \*P\<0.05, \*\*P\<0.01, vs. 0 µM/ml. NPC, nasopharyngeal carcinoma.](MMR-17-06-7513-g01){#f2-mmr-17-06-7513}

![Curcumol altered the expression levels of genes in the EMT pathway. (A) Expression of E-cadherin mRNA. (B) Expression of N-cadherin mRNA. (C) Western blot analysis of the expression of E-cadherin protein. (D) Western blot analysis of the expression of N-cadherin protein. (E) Quantification of the expression of E-cadherin protein. (F) Quantification of the expression of N-cadherin protein. Values are presented as the mean ± standard error of the mean. \*P\<0.05, \*\*P\<0.01, vs. 0 µM/ml. EMT, epithelial mesenchymal transition.](MMR-17-06-7513-g02){#f3-mmr-17-06-7513}

![Curcumol attenuated cancer progression *in vivo*. (A) Tumors removed from nude mice. (B) Tumor volume in the Curcumol and control groups. (C) Tumor weight in the Curcumol and control groups. Values are presented as the mean ± standard error of the mean. \*P\<0.05, \*\*P\<0.01, vs. control group.](MMR-17-06-7513-g03){#f4-mmr-17-06-7513}

![Curcumol altered the expression levels of genes in the EMT pathway *in vivo*. (A) Expression of E-cadherin indicated using western blotting. (B) Expression of N-cadherin indicated using western blotting. (C) Expression of TGF-β1 indicated using western blotting. (D) Secretion of TGF-β1 in the serum of transplanted tumor models in nude mice. Values are presented as the mean ± standard error of the mean. \*P\<0.05, \*\*P\<0.01, vs. control group. EMT, epithelial mesenchymal transition; TGF-β1, transforming growth factor-β1.](MMR-17-06-7513-g04){#f5-mmr-17-06-7513}
